Das kolorektale Karzinom liegt mit einer Inzidenz von etwa 70 000 Neuerkrankungen
in Deutschland mit an der Spitze aller Tumorerkrankungen; die Heilungsraten über alle
Patienten bzw. Stadien ist mit etwa 55 % nach wie vor schlecht. Durch optimierte
Therapiealgorithmen, neue Zytostatika/molekular gezielte Therapien und molekulare
Prädiktoren des Therapieerfolges sowie enge interdisziplinäre Zusammenarbeit darf
man in den kommenden Jahren auf eine Verbesserung der Prognose hoffen.
The colorectal carcinoma is among the most frequently occurring carcinomas in Germany
with an incidence of about 70000 new cases and the rate of cured cases of patients
or stages continues to be as low as 55 per cent. We may hope that the prognostic rate
will improve due to improved therapy algorithms, new therapies with cystomolecular
targeting and molecular predictors.
Key words
Colorectal cancer - liver metastases - guidelines - palliative therapy
Literatur
- 1
Amado R, Wolf M, Peeters M..
Wild–Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal
Cancer.
J Clin Oncol.
2008;
26
1626-1634
- 2
Schmiegel W. et al. .
S3–Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008. Ergebnis einer evidenzbasierten
Konsensuskonferenz (8.–9. Juni 2007). Update S3–Guideline „Colorectal Cancer” 2008.
Z Gastr.
2008;
46
799-840
- 3
Nordlinger B. et al. .
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable
livermetastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised
controlled trial.
Lancet.
2008;
371
1007-1016
- 4
Falcone A. et al. .
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan
(FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI)
as first–line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord
Ovest.
J Clin Oncol.
2007;
25
1670-1676
- 5
Van Cutsem E, Nowacki M, Lang I..
Randomized phase III study of irinotecan and 5–FU/FA with or without cetuximab in
the first–line treatment of patients with metastatic colorectal cancer (mCRC): The
CRYSTAL trial. ASCO Annual Meeting Proceedings.
J Clin Oncol.
2007;
25
- 6
Van Cutsem E, Lang I, D'haens G. et al. .
KRAS status and efficacy in the first–line treatment of patients with metastatic colorectal
cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience.
ASCO Annual Meeting Proceedings.
J Clin Oncol.
2008;
26
- 7
Grünberger B. et al. .
Bevacizumab, capecitabine and oxaliplatin as neoadjuvant therapy for patients with
potentially resectable metastatic colorectal cancer.
J Clin Oncol.
2008;
26
1830-1850
- 8
Cassidy J. et al. .
Surgery with curative intent in patients (pts) treated with first–line chemotherapy
(CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966.
ASCO Annual Meeting Proceedings.
J Clin Oncol.
2008;
26
- 9
Saltz LB. et al. .
Bevacizumab in combination with oxaliplatin–based chemotherapy as first–line therapy
in metastatic colorectal cancer: a randomized phase III study.
J Clin Oncol.
2008;
26
2013-2019
- 10
Folprecht G. et al. .
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between
tumour response and resection rates.
Ann Oncol.
2005;
16
1311-1319
- 11
Aloia T. et al. .
Liver histology and surgical outcome after preoperative chemotherapy with fluorouracil
plus oxaliplatin in colorectal cancer liver metastases.
J Clin Oncol.
2006;
24
4983-4990
- 12
Grothey A. et al. .
Survival of patients with advanced colorectal cancer improves with the availability
of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment.
J Clin Oncol.
2004;
22
1209-1214
- 13
Scheithauer W. et al. .
Randomised comparison of combination chemotherapy plus supportive care with supportive
care alone in patients with metastatic colorectal cancer.
BMJ.
1993;
306
752-755
- 14
Cunningham D. et al. .
Randomised trial of irinotecan plus supportive care versus supportive care alone after
fluorouracil failure for patients with metastatic colorectal cancer.
Lancet.
1998;
352
1413-1418
- 15
Jonker DJ, Karapetis CS, O'Callaghan J. et al. .
Cetuximab for the Treatment of Colorectal Cancer.
N Engl J Med.
2007;
357
2040-2048
- 16
Van Cutsem E. et al. .
Open–label phase III trial of panitumumab plus best supportive care compared with
best supportive care alone in patients with chemotherapy–refractory metastatic colorectal
cancer.
J Clin Oncol.
2007;
25
1658-1664
- 17
Earle. et al. .
Aggressiveness of cancer care near the end of life: is it a quality–of–care issue?.
J Clin Oncol.
2008;
26
3860-3866
Korrespondenz
Priv.–Doz. Dr. med. Ralf–Dieter Hofheinz
3. Medizinische Klinik Universitätsmedizin Mannheim
Theodor–Kutzer Ufer 1–3
68167 Mannheim
Fax: Fax: 0621/383-2488
Email: ralf.hofheinz@med3.ma.uni-heidelberg.de